The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 298.00
Bid: 298.00
Ask: 301.00
Change: 2.00 (0.68%)
Spread: 3.00 (1.007%)
Open: 300.00
High: 307.00
Low: 298.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS REPORTS: Elementis swings to profit; Hutchmed changes CEO

Thu, 03rd Mar 2022 13:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Elementis PLC - London-based speciality chemicals - Swings to profit in 2021, with pretax profit of USD5.8 million, up from a loss of USD68.8 million in 2020. Strong new business momentum, targeted pricing actions and volume recovery boost revenue by 17% in the year to USD880 million from USD751 million the year before. Dividends may be reinstated in the medium term, but remain suspended. For 2022, global supply chain issues and cost inflation are a concern, but it is off to "an encouraging start".

----------

Synthomer PLC - Essex-based chemicals company - Profit before tax rockets in 2021 to GBP283.9 million from GBP20.3 million in 2020, as revenue is up 42% to GBP2.33 billion from GBP1.64 billion. Underlying pretax profit more than doubles to GBP420.1 million from GBP160.0 million. Profit is being used to make "major inorganic and organic investments" to support further growth. In 2022 so far, nitrile latex demand is "subdued" as Covid eases and inventories of medical gloves are high, while all other divisions have started 2022 well. Final dividend is 21.3 pence, over double that of 8.3p in 2020, for a total in 2021 of 30.0p, up from 11.6p the prior year.

----------

Glanbia PLC - Kilkenny, Ireland-based nutrition company - Revenue comes in ahead of expectations for 2021 at EUR4.20 billion, up 9.8% from EUR3.82 billion in 2020. Profit before tax rises 21% to EUR158.0 million from EUR131.1 million. Says performance was driven by strong global consumer demand. A final dividend of 17.53 cents is proposed, bringing the year's total to 29.28 cents, up 10% on 2020, and launches new EUR50 million share buyback. Growth in revenue is expected for 2022, and says inflationary costs will be managed with higher sales prices.

----------

Galliford Try Holdings PLC - Uxbridge, England-based construction company - Pretax profit up to GBP7.1 million in first half ended December 31 from GBP4.1 million a year before. Revenue is up 10% to GBP594 million from GBP542 million in the prior year. Order book is up to GBP3.4 billion from GBP3.3 billion a year ago. The company boosts interim dividend by 83% to 2.2 pence from 1.2p the year before. Outlook for the rest of the year is positive, with 95% of projected revenue already secured.

----------

Empiric Student Property PLC - London-based owner and operator of student accommodation - Swings to profit in 2021, with a pretax profit of GBP29.2 million from a pretax loss of GBP24.0 million. Net rental inome drops 11% year-on-year to GBP32.9 million from GBP32.9 million, with total revenue down 6% to GBP56.0 million from GBP59.4 million. Dividends resume in fourth quarter, with payment of 2.5p, and targets fully covered and progressive dividends going forward, to increase as occupancy rates normalise. For the academic year starting in 2022, Empiric expects to come in at the top of its 85% to 95% target occupancy rate.

----------

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Total revenue for 2021 is USD356.1 million up 56% year-on-year from USD228.0 million. Loss before tax of USD215.7 million widens from USD189.7 million in FY20. Momentum is continuing into 2022, and it held over USD1 billion in cash on December 31. Christian Hogg retires as chief executive officer, after 22 years with the company and 15 years as CEO. Promotes Chief Scientific Officer Weiguo Su, a 17-year company veteran, to CEO. The changes are effective from Friday.

----------

AIB Group PLC - Dublin-based bank - Swings to pretax profit of EUR629 million in 2021 from a loss of EUR931 million. Net interest income drops 4% to EUR1.79 billion from EUR1.87 billion the prior year. Gross loans were down 2% to EUR56.5 billion from EUR59.4 billion. Recommends dividend of 4.5 pence per share for the year, with no dividend having been paid in 2021. AIB expects net interest income to be "stable" in 2022.

----------

Hunting PLC - London-based energy services - In 2021, revenue drops 17% to USD521.6 million from USD626.0 million in 2020, but pretax loss from operations narrows to USD85.5 million from USD223.0 million. Second half of 2021 lifted by improved trading and recovering commodity prices, after first half hit by global reduction in activity in oil & gas. A final dividend of 4.0 cents will be paid out for the year, unchanged from 2020. As Covid-related operational issues ease in its first quarter, it predicts a "much improved" 2022.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 13:47

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Read more
3 Jan 2023 10:28

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Read more
19 Dec 2022 19:29

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Nov 2022 11:30

Hutchmed refocuses strategy away from early-stage studies

(Sharecast News) - Hutchmed China updated the market on its strategy on Tuesday, following an "in-depth evaluation" of the business.

Read more
15 Nov 2022 10:52

Hutchmed China to shift strategy toward advanced assets in pipeline

(Alliance News) - Hutchmed (China) Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business.

Read more
14 Nov 2022 16:55

LONDON MARKET CLOSE: Europe ends higher but New York struggles

(Alliance News) - European equities surrendered some afternoon gains but made a bright start to the week on Monday, shaking off hawkish noise from the US Federal Reserve, while investors waited with bated breath for the outcome of talks between the leaders of the world's two leading economies.

Read more
14 Nov 2022 14:20

IN BRIEF: Hutchmed sees positive results for gastric cancer drug

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. Explains the drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase-three study in 703 patients, which the firm says is "clinically meaningful". Fruquintinib also shows a "statistically significant improvement" in secondary endpoints including objective response rate, disease control rate, and improved duration of response, Hutchmed adds. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

Read more
14 Nov 2022 10:27

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
14 Nov 2022 09:40

Hutchmed reports positive results from recent fruquintinib study

(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.

Read more
27 Oct 2022 14:27

IN BRIEF: Hutchmed begins phase II/III trial of fruquintinib

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib combination with sintilimab in China. The trial will explore the combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma - the most common type of kidney cancer. The first patient in China received the dose on Thursday, it says.

Read more
10 Oct 2022 10:24

Hutchmed begins sovleplenib trial for anaemia treatment in China

(Alliance News) - Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune haemolytic anaemia in China.

Read more
8 Sep 2022 11:02

Hutchmed posts positive results for CRC cancer treatment

(Alliance News) - Hutchmed China Ltd on Thursday said that its fruquintinib treatment reduced risk of death by 34% in metastatic colorectal cancer patients.

Read more
9 Aug 2022 10:04

Hutchmed notes dosing of first participant in IMG-004 study

(Alliance News) - Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.

Read more
8 Aug 2022 12:42

Hutchmed upbeat on latest study results for colorectal cancer treatment

(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).

Read more
8 Aug 2022 11:32

UPDATE: Hutchmed, AstraZeneca move lung cancer drug to phase 3 trial

(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.